Full history for every metric is available with a Kvantra account
Orchard Therapeutics plc (ORTX)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 2 | 3 | 3 | 0 | 7 |
| Operating profit | $m | -32 | |||||
| Net profit | $m | -40 | -230 | -163 | -152 | -36 | -8 |
| EPS reported | $ | -0.61 | |||||
| Operating cashflow per share | $ | -5.94 | |||||
| Capex per share | $ | 0.51 | |||||
| FCF per share | $ | -6.45 | |||||
| Free cash flow | $m | -83 | |||||
| Net debt | $m | -86 | |||||
| Book value equity | $m | 98 | |||||
| Book value per share | $ | 7.66 | |||||
| Number of shares | m | 12.82 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 0.48 | |||||
| P/S LTM | x | 6.78 | |||||
| P/FCF LTM | x | -0.57 | |||||
| EV/EBITDA LTM | x | -4.58 | |||||
| EV/Sales LTM | x | 5.30 | |||||
| Earnings Yield LTM | % | -16.65% | |||||
| FCF Yield | % | -174.23% | |||||
| Quality | |||||||
| ROE | % | -8.02% | |||||
| ROIC | % | -15.86% | |||||
| Operating margin | % | -452.22% | |||||
| Gross margin | % | 65.17% | |||||
| FCF/Sales | % | -1180.9% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | +1346.4% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -1.42 | |||||
| Net Debt/EBITDA | x | 1.28 | |||||
| EBIT/Net interest | x | -33.86 | |||||
| Net debt/market cap | % | -180.91% | |||||
| Net debt/Equity | x | -0.87 | |||||
| Gross debt/equity | x | 0.59 | |||||
Company overview
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Orchard Therapeutics plc (ORTX)
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free